Abstract
Neoplastic transformation is reportedly associated with alterations of the potassium transport across plasma and intracellular membranes. These alterations have been identified as crucial elements of the tumourigenic reprogramming of cells. Potassium channels may contribute to cancer initiation, malignant progression and therapy resistance of tumour cells. The book chapter focusses on (oncogenic) potassium channels frequently upregulated in different tumour entities, upstream and downstream signalling of these channels, their contribution to the maintenance of cancer stemness and the formation of an immunosuppressive tumour microenvironment. In addition, their role in adaptation to tumour hypoxia, metabolic reprogramming, as well as tumour spreading and metastasis is discussed. Finally, we discuss how (oncogenic) potassium channels may confer treatment resistance of tumours against radiation and chemotherapy and thus might be harnessed for new therapy strategies, for instance, by repurposing approved drugs known to target potassium channels.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alama A, Orengo AM, Ferrini S, Gangemi R (2012) Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies? Drug Discov Today 17:435–442. https://doi.org/10.1016/j.drudis.2011.02.005
Arcangeli A, Becchetti A (2017) hERG channels: from antitargets to novel targets for cancer therapy. Clin Cancer Res 23:3–5. https://doi.org/10.1158/1078-0432.Ccr-16-2322
Arcangeli A, Bianchi L, Becchetti A et al (1995) A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. J Physiol 489(Pt 2):455–471
Ataga KI, Smith WR, De Castro LM et al (2008) Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 111:3991–3997
Becchetti A, Petroni G, Arcangeli A (2019) Ion channel conformations regulate integrin-dependent signaling. Trends Cell Biol 29:298–307. https://doi.org/10.1016/j.tcb.2018.12.005
Bischof H, Burgstaller S, Springer A et al (2021) Potassium ions promote hexokinase-II dependent glycolysis. eScience 24:102346. https://doi.org/10.1016/j.isci.2021.102346
Bonito B, Sauter DR, Schwab A, Djamgoz MB, Novak I (2016) K(Ca)3.1 (IK) modulates pancreatic cancer cell migration, invasion and proliferation: anomalous effects on TRAM-34. Pflugers Arch 468:1865–1875. https://doi.org/10.1007/s00424-016-1891-9
Braun N, Klumpp D, Hennenlotter J, Bedke J, Duranton C, Bleif M, Huber SM (2015) UCP-3 uncoupling protein confers hypoxia resistance to renal epithelial cells and is upregulated in renal cell carcinoma. Sci Rep 5:13450
Brevet M, Fucks D, Chatelain D, Regimbeau JM, Delcenserie R, Sevestre H, Ouadid-Ahidouch H (2009) Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation. Pancreas 38:649–654. https://doi.org/10.1097/MPA.0b013e3181a56ebf
Catacuzzeno L, Aiello F, Fioretti B et al (2011) Serum-activated K and Cl currents underlay U87-MG glioblastoma cell migration. J Cell Physiol 226:1926–1933
Cázares-Ordoñez V, Pardo LA (2017) Kv10.1 potassium channel: from the brain to the tumors. Biochem Cell Biol 95:531–536. https://doi.org/10.1139/bcb-2017-0062
Chandy KG, Norton RS (2016) Immunology: channelling potassium to fight cancer. Nature 537:497–499. https://doi.org/10.1038/nature19467
Chen SZ, Jiang M, Zhen YS (2005) HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother Pharmacol 56:212–220. https://doi.org/10.1007/s00280-004-0960-5
Cherubini A, Pillozzi S, Hofmann G et al (2002) HERG K+ channels and beta1 integrins interact through the assembly of a macromolecular complex. Ann N Y Acad Sci 973:559–561
Chiang EY, Li T, Jeet S et al (2017) Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions. Nat Commun 8:14644. https://doi.org/10.1038/ncomms14644
Chimote AA, Hajdu P, Sfyris AM, Gleich BN, Wise-Draper T, Casper KA, Conforti L (2017) Kv1.3 channels mark functionally competent CD8+ tumor-infiltrating lymphocytes in head and neck cancer. Cancer Res 77:53–61. https://doi.org/10.1158/0008-5472.Can-16-2372
Chimote AA, Balajthy A, Arnold MJ et al (2018) A defect in KCa3.1 channel activity limits the ability of CD8(+) T cells from cancer patients to infiltrate an adenosine-rich microenvironment. Sci Signal 11. https://doi.org/10.1126/scisignal.aaq1616
Choi SY, Kim HR, Ryu PD, Lee SY (2017) Regulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460. BMC Pharmacol Toxicol 18:14. https://doi.org/10.1186/s40360-017-0118-9
Conforti L (2017) Potassium channels of T lymphocytes take center stage in the fight against cancer. J Immunother Cancer 5:2. https://doi.org/10.1186/s40425-016-0202-5
Cruz-Gregorio A, Martínez-Ramírez I, Pedraza-Chaverri J, Lizano M (2019) Reprogramming of energy metabolism in response to radiotherapy in head and neck squamous cell carcinoma. Cancers (Basel) 11. https://doi.org/10.3390/cancers11020182
D’Alessandro G, Catalano M, Sciaccaluga M et al (2013) KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death Dis 4:e773
De Marchi U, Sassi N, Fioretti B, Catacuzzeno L, Cereghetti GM, Szabò I, Zoratti M (2009) Intermediate conductance Ca2+-activated potassium channel (KCa3.1) in the inner mitochondrial membrane of human colon cancer cells. Cell Calcium 45:509–516. https://doi.org/10.1016/j.ceca.2009.03.014
Dittmann K, Mayer C, Rodemann HP, Huber SM (2013) EGFR cooperates with glucose transporter SGLT1 to enable chromatin remodeling in response to ionizing radiation. Radiother Oncol 107:247–251. https://doi.org/10.1016/j.radonc.2013.03.016
Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH (2011) Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol 18:1797–1804. https://doi.org/10.1245/s10434-011-1561-2
Du Y, Song W, Chen J et al (2019) The potassium channel KCa3.1 promotes cell proliferation by activating SKP2 and metastasis through the EMT pathway in hepatocellular carcinoma. Int J Cancer 145:503–516. https://doi.org/10.1002/ijc.32121
Eckert F, Schilbach K, Klumpp L et al (2018) Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of Cancer. Front Immunol 9:3018. https://doi.org/10.3389/fimmu.2018.03018
Eckert F, Zwirner K, Boeke S, Thorwarth D, Zips D, Huber SM (2019) Rationale for combining radiotherapy and immune checkpoint inhibition for patients with hypoxic tumors. Front Immunol 10:407. https://doi.org/10.3389/fimmu.2019.00407
Edalat L, Stegen B, Klumpp L et al (2016) BK K+ channel blockade inhibits radiation-induced migration/brain infiltration of glioblastoma cells. Oncotarget 7:14259–14278. https://doi.org/10.18632/oncotarget.7423
Eil R, Vodnala SK, Clever D et al (2016) Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537:539–543
Erdem M, Tekiner TA, Fejzullahu A et al (2015) herg1b expression as a potential specific marker in pediatric acute myeloid leukemia patients with HERG 897K/K genotype. Pediatr Hematol Oncol 32:182–192. https://doi.org/10.3109/08880018.2014.949941
Feske S (2019) CRAC channels and disease – from human CRAC channelopathies and animal models to novel drugs. Cell Calcium 80:112–116. https://doi.org/10.1016/j.ceca.2019.03.004
Feske S, Wulff H, Skolnik EY (2015) Ion channels in innate and adaptive immunity. Annu Rev Immunol 33:291–353. https://doi.org/10.1146/annurev-immunol-032414-112212
Fortunato A (2017) The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells. Cell Oncol (Dordr) 40:367–378. https://doi.org/10.1007/s13402-017-0328-6
Fortunato P, Pillozzi S, Tamburini A, Pollazzi L, Franchi A, La Torre A, Arcangeli A (2010) Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway. BMC Cancer 10:504
Frankenreiter S, Bednarczyk P, Kniess A et al (2017) cGMP-elevating compounds and ischemic conditioning provide cardioprotection against ischemia and reperfusion injury via cardiomyocyte-specific BK channels. Circulation 136:2337–2355. https://doi.org/10.1161/circulationaha.117.028723
Fu C, Cao CM, Xia Q, Yang J, Lu Y (2003) Reactive oxygen species and mitochondrial KATP-sensitive channels mediated cardioprotection induced by TNF-alpha during hypoxia and reoxygenation. Sheng Li Xue Bao 55:284–289
Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C (2009) Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun 390:743–749. https://doi.org/10.1016/j.bbrc.2009.10.042
García-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stühmer W, Pardo LA (2004) Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol 124:301–317. https://doi.org/10.1085/jgp.200409041
García-Quiroz J, García-Becerra R, Santos-Martínez N et al (2014) In vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors. BMC Cancer 14:745. https://doi.org/10.1186/1471-2407-14-745
García-Quiroz J, González-González ME, Díaz L et al (2019) Astemizole, an inhibitor of ether-à-go-go-1 potassium channel, increases the activity of the tyrosine kinase inhibitor gefitinib in breast cancer cells. Rev Invest Clin 71:186–194. https://doi.org/10.24875/ric.18002840
Gibhardt CS, Roth B, Schroeder I et al (2015) X-ray irradiation activates K+ channels via H2O2 signaling. Sci Rep 5:13861
Grimaldi A, D'Alessandro G, Golia MT et al (2016) KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages. Cell Death Dis 7:e2174. https://doi.org/10.1038/cddis.2016.73
Gu XQ, Pamenter ME, Siemen D, Sun X, Haddad GG (2014) Mitochondrial but not plasmalemmal BK channels are hypoxia-sensitive in human glioma. Glia 62:504–513. https://doi.org/10.1002/glia.22620
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645–659. https://doi.org/10.1016/j.cell.2009.06.034
Hartung F, Pardo LA (2016) Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin. Eur Biophys J 45:709–719. https://doi.org/10.1007/s00249-016-1149-7
Heise N, Palme D, Misovic M et al (2010) Non-selective cation channel-mediated Ca2+-entry and activation of Ca2+/calmodulin-dependent kinase II contribute to G2/M cell cycle arrest and survival of irradiated leukemia cells. Cell Physiol Biochem 26:597–608
Huang CL, Ruskin BH (1964) Determination of serum chlorpromazine metabolites in psychotic patients. J Nerv Ment Dis 139:381–386
Huang X, He Y, Dubuc AM et al (2015) EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci 18:1236–1246. https://doi.org/10.1038/nn.4088
Huber SM (2013) Oncochannels. Cell Calcium 53:241–255
Huber SM, Misovic M, Mayer C, Rodemann HP, Dittmann K (2012) EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. Radiother Oncol 103:373–379
Huber SM, Butz L, Stegen B, Klumpp D, Braun N, Ruth P, Eckert F (2013) Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol 4:212
Huber SM, Butz L, Stegen B, Klumpp L, Klumpp D, Eckert F (2015) Role of ion channels in ionizing radiation-induced cell death. Biochim Biophys Acta 1848:2657–2664. https://doi.org/10.1016/j.bbamem.2014.11.004
Hui C, Lan Z, Yue-li L, Li-lin H, Li-lin H (2015) Knockdown of Eag1 expression by RNA interference increases chemosensitivity to cisplatin in ovarian cancer cells. Reprod Sci 22:1618–1626. https://doi.org/10.1177/1933719115590665
Imlach WL, Finch SC, Dunlop J, Meredith AL, Aldrich RW, Dalziel JE (2008) The molecular mechanism of “ryegrass staggers,” a neurological disorder of K+ channels. J Pharmacol Exp Ther 327:657–664
Jensen BS, Strobaek D, Christophersen P et al (1998) Characterization of the cloned human intermediate-conductance Ca2+-activated K+ channel. Am J Phys 275:C848–C856. https://doi.org/10.1152/ajpcell.1998.275.3.C848
Kachmar JF, Boyer PD (1953) Kinetic analysis of enzyme reactions. II. The potassium activation and calcium inhibition of pyruvic phosphoferase. J Biol Chem 200:669–682
Kale VP, Amin SG, Pandey MK (2015) Targeting ion channels for cancer therapy by repurposing the approved drugs. Biochim Biophys Acta 1848:2747–2755. https://doi.org/10.1016/j.bbamem.2015.03.034
Kammerer S, Sokolowski A, Hackl H et al (2016) KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients. Oncotarget 7:84705–84717. https://doi.org/10.18632/oncotarget.13224
Kato M, Chuang JL, Tso SC, Wynn RM, Chuang DT (2005) Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl domain 2 of human pyruvate dehydrogenase complex. EMBO J 24:1763–1774. https://doi.org/10.1038/sj.emboj.7600663
Klumpp D, Misovic M, Szteyn K, Shumilina E, Rudner J, Huber SM (2016a) Targeting TRPM2 channels impairs radiation-induced cell cycle arrest and fosters cell death of T cell leukemia cells in a Bcl-2-dependent manner. Oxidative Med Cell Longev 2016:8026702. https://doi.org/10.1155/2016/8026702
Klumpp L, Sezgin EC, Eckert F, Huber SM (2016b) Ion channels in brain metastasis. Int J Mol Sci 17
Klumpp D, Frank SC, Klumpp L et al (2017) TRPM8 is required for survival and radioresistance of glioblastoma cells. Oncotarget 8:95896–95913. https://doi.org/10.18632/oncotarget.21436
Klumpp L, Sezgin EC, Skardelly M, Eckert F, Huber SM (2018) KCa3.1 channels and glioblastoma: in vitro studies. Curr Neuropharmacol 16:627–635. https://doi.org/10.2174/1570159x15666170808115821
Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ (1984) Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 11:259–269
Koshy S, Wu D, Hu X et al (2013) Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One 8:e76740. https://doi.org/10.1371/journal.pone.0076740
Kulawiak B, Kudin AP, Szewczyk A, Kunz WS (2008) BK channel openers inhibit ROS production of isolated rat brain mitochondria. Exp Neurol 212:543–547
Lacruz RS, Feske S (2015) Diseases caused by mutations in ORAI1 and STIM1. Ann N Y Acad Sci 1356:45–79. https://doi.org/10.1111/nyas.12938
Lastraioli E, Lottini T, Bencini L, Bernini M, Arcangeli A (2015) hERG1 potassium channels: novel biomarkers in human solid cancers. Biomed Res Int 2015:896432. https://doi.org/10.1155/2015/896432
Leanza L, Biasutto L, Manago A, Gulbins E, Zoratti M, Szabo I (2013) Intracellular ion channels and cancer. Front Physiol 4:227. https://doi.org/10.3389/fphys.2013.00227
Lee K, McKenna F, Rowe IC, Ashford ML (1997) The effects of neuroleptic and tricyclic compounds on BKCa channel activity in rat isolated cortical neurones. Br J Pharmacol 121:1810–1816
Lehmann DF, Eggleston WD, Wang D (2018) Validation and clinical utility of the hERG IC50:Cmax ratio to determine the risk of drug-induced Torsades de pointes: a meta-analysis. Pharmacotherapy 38:341–348. https://doi.org/10.1002/phar.2087
Li F, Sonveaux P, Rabbani ZN et al (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26:63–74. https://doi.org/10.1016/j.molcel.2007.02.024
Li B, Jie W, Huang L et al (2014a) Nuclear BK channels regulate gene expression via the control of nuclear calcium signaling. Nat Neurosci 17:1055–1063. https://doi.org/10.1038/nn.3744
Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ (2014b) XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 123:2148–2152. https://doi.org/10.1182/blood-2013-11-538686
Li L, Li J, Zuo Y, Dang D, Frost JA, Yang Q (2019) Activation of KCNQ channels prevents paclitaxel-induced peripheral neuropathy and associated neuropathic pain. J Pain 20:528–539. https://doi.org/10.1016/j.jpain.2018.11.001
Liang XJ, Taylor B, Cardarelli C et al (2005) Different roles for K+ channels in cisplatin-resistant cell lines argue against a critical role for these channels in cisplatin resistance. Anticancer Res 25:4113–4122
Liu X, Chang Y, Reinhart PH, Sontheimer H, Chang Y (2002) Cloning and characterization of glioma BK, a novel BK channel isoform highly expressed in human glioma cells. J Neurosci 22:1840–1849. https://doi.org/10.1523/jneurosci.22-05-01840.2002
Liu H, Huang J, Peng J, Wu X, Zhang Y, Zhu W, Guo L (2015a) Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Mol Cancer 14:59. https://doi.org/10.1186/s12943-015-0298-0
Liu Y, Zhao L, Ma W et al (2015b) The blockage of KCa3.1 channel inhibited proliferation, migration and promoted apoptosis of human hepatocellular carcinoma cells. J Cancer 6:643–651. https://doi.org/10.7150/jca.11913
Madreiter-Sokolowski CT, Ramadani-Muja J, Ziomek G et al (2019) Tracking intra- and inter-organelle signaling of mitochondria. FEBS J 286:4378–4401. https://doi.org/10.1111/febs.15103
Mohr CJ, Gross D, Sezgin EC, Steudel FA, Ruth P, Huber SM, Lukowski R (2019a) KCa3.1 channels confer radioresistance to breast cancer cells. Cancers (Basel) 11. https://doi.org/10.3390/cancers11091285
Mohr CJ, Steudel FA, Gross D et al (2019b) Cancer-associated intermediate conductance Ca(2+)-activated K+ channel K(Ca)3.1. Cancers (Basel) 11. https://doi.org/10.3390/cancers11010109
Mohr CJ, Schroth W, Murdter TE et al (2020) Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models. Br J Pharmacol. https://doi.org/10.1111/bph.15147
Nilius B, Wohlrab W (1992) Potassium channels and regulation of proliferation of human melanoma cells. J Physiol 445:537–548. https://doi.org/10.1113/jphysiol.1992.sp018938
Ong ST, Ng AS, Ng XR et al (2019) Extracellular K+ dampens T cell functions: implications for immune suppression in the tumor microenvironment. Bioelectricity 1:169–179
Paggio A, Checchetto V, Campo A et al (2019) Identification of an ATP-sensitive potassium channel in mitochondria. Nature 572:609–613. https://doi.org/10.1038/s41586-019-1498-3
Palme D, Misovic M, Schmid E, Klumpp D, Salih HR, Rudner J, Huber SM (2013) Kv3.4 potassium channel-mediated electrosignaling controls cell cycle and survival of irradiated leukemia cells. Pflugers Arch 465:1209–1221. https://doi.org/10.1007/s00424-013-1249-5
Palme D, Misovic M, Ganser K, Klumpp L, Salih HR, Zips D, Huber SM (2020) hERG K(+) channels promote survival of irradiated leukemia cells. Front Pharmacol 11:489. https://doi.org/10.3389/fphar.2020.00489
Pardo LA, Stuhmer W (2014) The roles of K(+) channels in cancer. Nat Rev Cancer 14:39–48. https://doi.org/10.1038/nrc3635
Park JH, Park SJ, Chung MK et al (2010) High expression of large-conductance Ca2+-activated K+ channel in the CD133+ subpopulation of SH-SY5Y neuroblastoma cells. Biochem Biophys Res Commun 396:637–642. https://doi.org/10.1016/j.bbrc.2010.04.142
Petroni G (2020) Targeting potassium channels and autophagy to defeat chemoresistance. Mol Cell Oncol 7:1745038. https://doi.org/10.1080/23723556.2020.1745038
Pillozzi S, Arcangeli A (2010) Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv Exp Med Biol 674:55–67
Pillozzi S, Brizzi MF, Balzi M et al (2002) HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 16:1791–1798
Pillozzi S, Brizzi MF, Bernabei PA et al (2007) VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110:1238–1250
Pillozzi S, Masselli M, De Lorenzo E et al (2011) Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117:902–914
Pillozzi S, D'Amico M, Bartoli G et al (2018) The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome cisplatin resistance in colorectal cancer cells. Br J Cancer 118:200–212. https://doi.org/10.1038/bjc.2017.392
Pointer KB, Clark PA, Eliceiri KW, Salamat MS, Robertson GA, Kuo JS (2017) Administration of non-torsadogenic human ether-a-go-go-related gene inhibitors is associated with better survival for high hERG-expressing glioblastoma patients. Clin Cancer Res 23:73–80. https://doi.org/10.1158/1078-0432.Ccr-15-3169
Quiroga-Roger D, Babul J, Guixe V (2015) Role of monovalent and divalent metal cations in human ribokinase catalysis and regulation. Biometals 28:401–413. https://doi.org/10.1007/s10534-015-9844-x
Roberta P, Andrea M, Michele A et al (2020) Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family. Redox Biology 37:101705. https://doi.org/10.1016/j.redox.2020.101705
Rosa P, Sforna L, Carlomagno S et al (2017) Overexpression of large-conductance calcium-activated potassium channels in human glioblastoma stem-like cells and their role in cell migration. J Cell Physiol 232:2478–2488. https://doi.org/10.1002/jcp.25592
Rose IA, Warms JVB (1982) Stability of hexokinase II in vitro and in ascites tumor cells. Arch Biochem Biophys 213:625–634. https://doi.org/10.1016/0003-9861(82)90592-6
Roth B, Huber SM (2020) Ion transport and radioresistance. Rev Physiol Biochem Pharmacol. https://doi.org/10.1007/112_2020_33
Roth B, Gibhardt CS, Becker P et al (2015) Low-dose photon irradiation alters cell differentiation via activation of hIK channels. Pflugers Arch 467:1835–1849. https://doi.org/10.1007/s00424-014-1601-4
Ruggieri P, Mangino G, Fioretti B et al (2012) The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. PLoS One 7:e47825
Sales TT, Resende FF, Chaves NL, Titze-De-Almeida SS, Báo SN, Brettas ML, Titze-De-Almeida R (2016) Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomide. Oncol Lett 12:2581–2589. https://doi.org/10.3892/ol.2016.4992
Samuel P, Pink RC, Caley DP, Currie JM, Brooks SA, Carter DR (2016) Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells. Tumour Biol 37:2565–2573. https://doi.org/10.1007/s13277-015-4081-z
Sausbier U, Sausbier M, Sailer CA, Arntz C, Knaus HG, Neuhuber W, Ruth P (2006) Ca2+ -activated K+ channels of the BK-type in the mouse brain. Histochem Cell Biol 125:725–741
Schickling BM, Aykin-Burns N, Leslie KK, Spitz DR, Korovkina VP (2011) An inhibitor of K+ channels modulates human endometrial tumor-initiating cells. Cancer Cell Int 11:25. https://doi.org/10.1186/1475-2867-11-25
Schwab A, Fabian A, Hanley PJ, Stock C (2012) Role of ion channels and transporters in cell migration. Physiol Rev 92:1865–1913. https://doi.org/10.1152/physrev.00018.2011
Shen F-F, Dai S-Y, Wong N-K, Deng S, Wong AS-T, Yang D (2020) Mediating K+/H+ transport on organelle membranes to selectively eradicate cancer stem cells by a small molecule. J Am Chem Soc 142(24):10769–10779
Singh H, Lu R, Bopassa JC, Meredith AL, Stefani E, Toro L (2013) MitoBK(Ca) is encoded by the Kcnma1 gene, and a splicing sequence defines its mitochondrial location. Proc Natl Acad Sci U S A 110:10836–10841. https://doi.org/10.1073/pnas.1302028110
Sontheimer H (2008) An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med (Maywood) 233:779–791
Stegen B, Butz L, Klumpp L, Zips D, Dittmann K, Ruth P, Huber SM (2015) Ca2+-activated IK K+ channel blockade radiosensitizes glioblastoma cells. Mol Cancer Res 13:1283–1295. https://doi.org/10.1158/1541-7786.Mcr-15-0075
Stegen B, Klumpp L, Misovic M et al (2016) K(+) channel signaling in irradiated tumor cells. Eur Biophys J 45:585–598. https://doi.org/10.1007/s00249-016-1136-z
Steinle M, Palme D, Misovic M et al (2011) Ionizing radiation induces migration of glioblastoma cells by activating BK K(+) channels. Radiother Oncol 101:122–126. https://doi.org/10.1016/j.radonc.2011.05.069
Steudel FA, Mohr CJ, Stegen B et al (2017) SK4 channels modulate Ca(2+) signalling and cell cycle progression in murine breast cancer. Mol Oncol 11:1172–1188
Storck H, Hild B, Schimmelpfennig S et al (2017) Ion channels in control of pancreatic stellate cell migration. Oncotarget 8:769–784. https://doi.org/10.18632/oncotarget.13647
Stowe DF, Gadicherla AK, Zhou Y et al (2013) Protection against cardiac injury by small Ca(2+)-sensitive K(+) channels identified in guinea pig cardiac inner mitochondrial membrane. Biochim Biophys Acta 1828:427–442. https://doi.org/10.1016/j.bbamem.2012.08.031
Tarcha EJ, Olsen CM, Probst P, Peckham D, Muñoz-Elías EJ, Kruger JG, Iadonato SP (2017) Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial. PLoS One 12:e0180762. https://doi.org/10.1371/journal.pone.0180762
Teisseyre A, Palko-Labuz A, Sroda-Pomianek K, Michalak K (2019) Voltage-gated potassium channel Kv1.3 as a target in therapy of cancer. Front Oncol 9:933. https://doi.org/10.3389/fonc.2019.00933
Trebak M, Kinet JP (2019) Calcium signalling in T cells. Nat Rev Immunol 19:154–169. https://doi.org/10.1038/s41577-018-0110-7
Voos P, Fuck S, Weipert F et al (2018) Ionizing radiation induces morphological changes and immunological modulation of Jurkat cells. Front Immunol 9:922. https://doi.org/10.3389/fimmu.2018.00922
Wang Y (2011) Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med Chem 7:106–111. https://doi.org/10.2174/157340611794859307
Wang ZJ, Soohoo SM, Tiwari PB, Piszczek G, Brelidze TI (2020) Chlorpromazine binding to the PAS domains uncovers the effect of ligand modulation on EAG channel activity. J Biol Chem 295:4114–4123. https://doi.org/10.1074/jbc.RA119.012377
Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530. https://doi.org/10.1085/jgp.8.6.519
Watkins S, Sontheimer H (2011) Hydrodynamic cellular volume changes enable glioma cell invasion. J Neurosci 31:17250–17259. https://doi.org/10.1523/jneurosci.3938-11.2011
Wonderlin WF, Strobl JS (1996) Potassium channels, proliferation and G1 progression. J Membr Biol 154:91–107. https://doi.org/10.1007/s002329900135
Wulff H, Castle NA (2010) Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol 3:385–396. https://doi.org/10.1586/ecp.10.11
Xie H, Simon MC (2017) Oxygen availability and metabolic reprogramming in cancer. J Biol Chem 292:16825–16832. https://doi.org/10.1074/jbc.R117.799973
Xu H, Lai W, Zhang Y et al (2014) Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer 14:330. https://doi.org/10.1186/1471-2407-14-330
Zhang R, Tian P, Chi Q et al (2012) Human ether-à-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer. Oncol Rep 27:433–440. https://doi.org/10.3892/or.2011.1515
Zhang Y, Zhang P, Chen L, Zhao L, Zhu J, Zhu T (2019) The long non-coding RNA-14327.1 promotes migration and invasion potential of endometrial carcinoma cells by stabilizing the potassium channel Kca3.1. Onco Targets Ther 12:10287–10297. https://doi.org/10.2147/ott.S226737
Acknowledgement
FE was partly funded by the Else-Kroener-Fresenius Research Foundation (Grant 2015_Kolleg.14) and the Gesellschaft für Kinderkrebsforschung, SMH by a grant from the German Cancer Aid (70112872, 70113144). HB is a fellow of the Alexander von Humboldt Foundation. RL received funding from the ICEPHA Graduate Program “Membrane-associated Drug Targets in Personalized Cancer Medicine”.
Conflict of Interest
All authors declare no competing interests.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ganser, K., Klumpp, L., Bischof, H., Lukowski, R., Eckert, F., Huber, S.M. (2021). Potassium Channels in Cancer. In: Gamper, N., Wang, K. (eds) Pharmacology of Potassium Channels. Handbook of Experimental Pharmacology, vol 267. Springer, Cham. https://doi.org/10.1007/164_2021_465
Download citation
DOI: https://doi.org/10.1007/164_2021_465
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-84051-8
Online ISBN: 978-3-030-84052-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)